LAS VEGAS, NV -- (Marketwire) -- 07/31/10 -- Pro-Pointer, Inc. (PINKSHEETS: PPII), through its wholly owned subsidiary, Coenzyme-A Technologies, Inc., is pleased to announce its latest innovative proprietary formula the "PURE COENZYME-A." "Our product duplicates the biological functions used by the human body in the creation of cellular energy," stated Nickolaos Skoaras, PhD., President / CEO of Coenzyme-A Technologies, Inc. "Coenzyme-A is the most active metabolic enzyme in the human body and as the initiator of the human body's primary energy cycle; this is the purest form of energy there is," Skouras added. Coenzyme-A is energy pure and simple. Besides its indispensable energy work, Coenzyme-A initiates the synthesis of a wide variety of other essential substances. These include acetylcholine (the key neurotransmitter in the brain), the steroid hormones (produced in the adrenal glands) and the sex hormones. It supports immune function, including the repair of DNA and RNA, plus healing from physical injury. It facilitates the manufacture of important components of connective tissue necessary to joint health, particularly chondroitin sulfate and hyaluronic acid. Lastly, Coenzyme-A retards the development of lactic acid build up during aerobic exercise preventing sore and stiff muscles.

ABOUT COENZYME-A TECHNOLOGIES, INC. -- Coenzyme-A Technologies, Inc. is an innovative company that has applied new technology to the formulation and manufacture of a series of proprietary products which address nutritional deficiencies that result from the stress of modern day living, chemical imbalances within the body, and the deleterious effects of aging. Coenzyme-A is the first nutraceutical manufacture and utilization of cellular Coenzyme-A (The Master Coenzyme). Coenzyme-A contains a specific set of substrates that are designed to assist the body in converting fats, carbohydrates and proteins into energy at the cellular level. See Company website -- www.coenzyme-a.com.

FORWARD-LOOKING STATEMENTS
The information contained in this release, other than historical information, consists of forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Such forward-looking statements involve known and unknown risks and uncertainties, including all business uncertainties relating to product development, marketing, market acceptance, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.